News

In a trial milestone, participants in the third patient group of the ASPIRO Phase 1/2a study (NCT06344026) are now receiving the commercial formulation of ANPD001, Aspen Neuroscience’s cell therapy candidate for Parkinson’s disease. While participants in earlier groups also received ANPD001, the third group is the…

The first European patients in Askbio‘s Phase 2 clinical trial of AB-1005, an experimental gene therapy for Parkinson’s disease, have been randomly assigned to treatment groups. The study, REGENERATE-PD (NCT06285643), has begun randomizing participants at sites in Poland and the U.K. Trial sites in Germany are…

The first patient has been dosed in exPDite-2, a registrational Phase 3 clinical trial testing the safety and efficacy of bemdaneprocel, an investigational stem cell therapy that Bluerock Therapeutics is developing for Parkinson’s disease. The trial (NCT06944522), originally scheduled to begin earlier this year, is recruiting…

Gain Therapeutics has launched a nine-month extension of its clinical trial testing GT-02287 as a Parkinson’s disease treatment. More than half of the patients who received GT-02287 for about three months as part of the Phase 1b clinical trial (NCT06732180), which is expected to be completed at…

Interactions between receptors for ghrelin, the so-called hunger hormone, and the chemical signaling molecule dopamine may go awry in Parkinson’s disease, potentially leading to chronic constipation — a symptom that the Australian scientists behind this new research called “debilitating” for many people with the condition. To learn more about…

The Parkinson’s Foundation will organize events in 20 U.S. cities this fall as part of Moving Day, a walk to increase awareness of Parkinson’s disease and raise funds for research. “Moving Day is much more than a fundraiser,” John Poma, a member of the foundation’s People with…

The Michael J. Fox Foundation (MJFF) is funding work to develop imaging technology for monitoring toxic proteins in Parkinson’s disease. Xingimaging said it and its partner Synusight Biotech will use the $3.84 million grant to fund studies and work toward clinical application of their compound, 18F-FD4.

Researchers have shed light on how alpha-synuclein oligomers, small soluble protein clusters linked to Parkinson’s disease, may disrupt nerve cell function by forming dynamic, reversible pores in their cell membrane. By developing a novel assay that enabled real-time visualization of how these oligomers interact with tiny artificial vesicles resembling…

People with Parkinson’s disease who stay active while in the hospital may recover faster and live longer, according to a study. The research, conducted by the Parkinson’s Foundation in partnership with University Hospitals, found that patients who moved at least three times a day — as the Parkinson’s…

Neu Health said it’s joining an incubator program that will help it expand its flagship product, a smartphone app that lets people with Parkinson’s disease and dementia track their symptoms from home, in the U.S. market. The UK-based company said it has been selected to join the U.S.